Probuphine Offers Hope for Long Term Opioid Addiction
Titan Pharmaceuticals is in phase III of its clinical trials for Probuphine, the company’s opiate addiction treatment that, by using its proprietary ProNeura drug delivery system, delivers buprenorphine at a constant, therapeutic level for a period of six months.
Buprenorphine is the partial opiate agonist found in the sublingual pill Suboxone. Probuphine is inserted under the skin in a simple office procedure that requires about fifteen minutes, and thus far, trials have shown a considerable amount of success.
The benefits of a subcutaneous delivery system are that it eliminates or significantly mitigates the inconsistency of compliance, varying levels of the drug in the blood, and the potential for abuse.
Source: Titan Pharmaceuticals
Date: May 5, 2008